Mandal PK, Saharan S, Tripathi M, Murari G. Brain glutathione levels--a novel biomarker for mild cognitive impairment. Biol Psychiatry. 2015;78(10):702-710. doi:10.1016/j.biopsych.2015.04.005
Several GDF-15 agonists are undergoing early phase clinical trials including NNC0247-0829 and JNJ-9090/CIN-109
At AyaFusion, peptide therapy is never about chasing outcomesits about matching the right tool to the right body at the right time
Researchers exploring peptide science often seek reliable information about peptide compounds, quality standards, and sourcing considerations within Australia
Hypersensitivity reactions have been reported with Emgality
The implications extend beyond diabetes, with broad applications in oncology, neurodegenerative, and inflammatory diseases, potentially accelerating the development of new treatments